A phase III clinical trial assessing KTX-1161
Latest Information Update: 22 Mar 2023
At a glance
- Drugs SCO 116 (Primary)
- Indications Corneal injuries; Diabetic nephropathies; Eye disorders; Fuchs' endothelial dystrophy; Lung disorders; Non-alcoholic steatohepatitis; Renal failure; Skin disorders
- Focus Registrational; Therapeutic Use
- Sponsors Kuria Therapeutics
Most Recent Events
- 22 Mar 2023 New trial record